Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqilishui formula is a traditional Chinese medicine (TCM) herbal formulation under investigation for the treatment of sepsis-induced myocardial dysfunction (SIMD). The pathogenesis of SIMD in TCM is described as "deficiency of Qi with water overflow and blood stasis and toxin blocking the channels." The Yiqilishui formula is designed to invigorate Qi, promote diuresis, detoxify, and unblock channels. It is administered as granules orally or via nasogastric tube. Its mechanism involves supporting cardiac function and reducing inflammation through multi-targeted herbal actions typical of TCM formulas. Clinical trials are ongoing to evaluate its efficacy and safety in combination with standard Western medical care for SIMD[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqilishui formula.